Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 8/20 | 0.43 |
| ▸ | DRD4 | P21917 | 8/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5456346 | 0.89 | ALDH1A1 (0.52) | ALDH1A1DRD2DRD4 | |
| SCHEMBL5453468 | 0.88 | LMNA (0.53) | ALDH1A1DRD2DRD4POLBGAA | |
| SCHEMBL5453534 | 0.87 | KMT2A (0.45) | ALDH1A1DRD2DRD4POLBGAA | |
| SCHEMBL5451186 | 0.86 | SMN1; SMN2 (0.46) | ALDH1A1DRD2DRD4POLBGAA | |
| SCHEMBL5453789 | 0.85 | NPC1 (0.46) | ALDH1A1DRD2DRD4GAAL3MBTL1 | |
| SCHEMBL5453866 | 0.84 | SMN1; SMN2 (0.43) | ALDH1A1DRD2DRD4 | |
| SCHEMBL5450007 | 0.84 | DRD2 (0.45) | ALDH1A1DRD2DRD4POLBGAA | |
| SCHEMBL5456173 | 0.82 | NPSR1 (0.43) | ALDH1A1DRD2DRD4GAA | |
| SCHEMBL5447846 | 0.82 | LMNA (0.51) | ALDH1A1DRD2DRD4GAAL3MBTL1 | |
| SCHEMBL5461488 | 0.81 | MAPT (0.53) | ALDH1A1DRD2DRD4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1660454-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | Vernalis (R&D) Limited (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005005392-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | ALDH1A1 489/4885DRD2 1065/4885DRD4 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.